Bright Angel Therapeutics

Bright Angel Therapeutics is a preclinical company headquartered in Toronto, dedicated to developing new drugs to address the growing global public health antifungal crisis. The company's discovery efforts focus on molecules that inhibit stress response pathways, which are considered central to the emergence of fungal resistance. Bright Angel was co-founded by Schrödinger and leverages the Schrödinger platform to design potent fungal-selective inhibitors.